Small intestinal bacterial overgrowth (SIBO) manifests with a variety of gastrointestinal symptoms, including bloating, flatulence, abdominal pain, nausea, dyspepsia, fatigue, diarrhea, and constipation [1] . SIBO has been implicated as a cause of hepatic encephalopathy and of d-lactic acidosis in patients with short bowel syndrome [2, 3] . Moreover, SIBO is associated with a variety of conditions outside of the gastrointestinal system, including rosacea [4], restless legs syndrome [5] , interstitial cystitis [6] , and chronic prostatitis [7] , and correlates with the level of somatic pain in fibromyalgia [8] . Along these lines, recent studies have reported a link between SIBO and cardiovascular disease.
significantly increased among patients with SIBO compared to patients without SIBO (9.5 vs 4.2 µg/L, p = 0.02). Correspondingly, arterial pulse wave velocity, which increases when there is an increase in arterial stiffness, was increased among patients with SIBO compared to that observed in the group without SIBO (10.25 vs 7.68 m/s, p = 0.002). The authors concluded, then, that SIBO is associated with reduced MGP activation as well as arterial stiffening, regarded as important indicators of subclinical atherosclerosis [9] .
In the current issue of Digestive Diseases and Sciences, Fialho et al. [11] expand upon this work by demonstrating a previously undescribed association between SIBO and coronary artery disease (CAD). In their study, they retrospectively reviewed medical records at a single tertiary care center in order to identify all patients who underwent a glucose hydrogen/methane breath test. Records were crossreferenced to identify 160 patients who had undergone left heart catheterization with coronary angiography at the same center. These records were reviewed to determine the presence and extent of CAD. Importantly, widely recognized risk factors for CAD such as age, smoking, diabetes, hypertension, obesity, dyslipidemia, and metabolic syndrome were identified and adjusted for in this study.
CAD was significantly more prevalent among patients with SIBO compared to those without SIBO (78.9 vs 38.6%, p < 0.001), a pattern that persisted even when the interval between breath testing and coronary angiography was narrowed to 6 months or 1 year. Intriguingly, there were also an increased number of vessels affected by CAD among patients with SIBO compared to those without. After adjusting for traditional risk factors for CAD, SIBO continued to be associated with CAD (OR 7.18; 95% CI 3.09-16.67; p < 0.001).
The currently accepted criteria suggest that a rise of ≥ 20 p.p.m. from baseline in hydrogen by 90 min should be considered a positive test for SIBO and that an absolute level of ≥ 10 p.p.m. should be considered positive for methane [12] . In this study, the glucose breath test was considered positive for SIBO when there was either (1) an increase in hydrogen and/or methane by > 20 parts per million (p.p.m.) above basal value or (2) an increase in hydrogen and/or methane by > 12 p.p.m. between minimal and maximal values after glucose ingestion within three hours after the administration of glucose. These diagnostic criteria may have increased the number of patients testing positive for SIBO. We encourage researchers to use the currently accepted criteria to facilitate the reproducibility and comparability of studies related to SIBO.
Of the 90 patients who tested positive for SIBO in this study, 85 (94.4%) had elevated hydrogen levels and 77 (85.6%) had elevated methane levels, an unusually high rate of methane positivity. Excess methane production even among patients with ongoing GI symptoms is generally 10-20%. The largest study in this field studying 12,183 lactulose breath tests has reported a methane positivity rate of 19.5% [13] . The reasons for the unusually high rate of methane positivity in this study are not immediately evident. Further studies are needed to assess whether methanogenic microorganisms are specifically linked to CAD.
Lastly, as Fialho et al. [11] recognize, despite the association between SIBO and CAD demonstrated in this paper, no conclusions can be drawn about causality of the relationship. While the work by Ponziani et al. linking SIBO and atherosclerosis through the vitamin K-dependent action of MGP suggests a causal relationship, elucidation of an underlying mechanism linking SIBO and CAD is absent in the present study. While large, long-term, controlled prospective studies would be necessary to prove a causal relationship between SIBO and CAD, studies demonstrating possible molecular mechanisms by which SIBO may lead to the development of CAD may be more feasible. Moreover, given the multifactorial nature of CAD, substantial attention should be paid to control for known modifiable and non-modifiable risk factors of CAD.
The medical community are only beginning to understand the complex relationship between gut microbiota, its dysregulation as found in SIBO, and a host of other conditions. Studies such as the one by Fialho et al. should be commended for adding to the characterization of these interactions. As physicians gain increased understanding of these relationships, the door is opened to the possibility of manipulating gastrointestinal conditions in order to affect the treatment of an ever-expanding number of potentially gut microbiome-associated diseases.
